tbuckley/cabot-search huggingface dataset:
Visit and treatment patterns over time among elderly patients (pts) with M1 prostate cancer (PC): An analysis using SEER-Medicare
Authors: A. Hussain, E. Onukwugha, B. Seal, C. D. Mullins
Journal: Journal of Clinical Oncology (2009)

5170 Background: Treatment options for the management of pts diagnosed with M1 PC have evolved over time. It is unknown whether visits to medical oncologists/hematologist oncologists (MOH) and treatment patterns are also changing over time. The objective of this study is to examine changes in visit and treatment patterns over time. Methods: A retrospective analysis of SEER Medicare data included pts diagnosed with M1 PC from 1994–2002 (age &gt; 65 years) and residing in SEER registries that were present for the entire period. The study included pts with a post-diagnosis visit to a urologist; pts who saw a MOH prior to the urologist visit were excluded. Pts were grouped as 1) no MOH visit, 2) MOH visit w/in 3 mos of a urologist visit, 3) MOH visit =&gt; 3 mos after a urologist visit. Treatment with hormone therapy or chemotherapy was defined as 1) none received; 2) timely (i.e. within 6 mos of diagnosis); and 3) delayed, i.e. =&gt; 6 mos following the diagnosis. Time periods were defined as early (1994–1996), middle (1997–1999) and late (2000–2002). Results: 3,269 pts (mean age 77, 81% white) were available for analysis. Ninety-three percent of pts received treatment. Thirty-eight percent of pts saw a MOH during the study period; over the study period (early; middle; late) 13% (10%; 13%; 17%) of pts had a timely visit to the MOH and 25% (24%; 28%; 25%) had a delayed visit to the MOH. The proportion of patients seeing a MOH increased (34%; 41%; 42%, p &lt; 0.001) and the proportion of treated pts increased (93%; 93%; 95%, p = 0.03) over the early, middle, and late periods. Conclusions: Approximately one-third of patients with M1 disease and a post-diagnosis urologist visit also see a medical oncologist. The vast majority of these patients receive treatment. Over time, a larger proportion of patients are seeing medical oncologists. [Table: see text]
Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).
Authors: Brendan John Guercio, Alan P. Venook, Donna Niedzwiecki, Sui Zhang, Kaori Sato, Charles S. Fuchs, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Erin Van Blarigan, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Jeffrey A. Meyerhardt
Journal: Journal of Clinical Oncology (2017)

659 Background: Regular physical activity (PA) is associated with reduced risk of recurrence and mortality in non-metastatic colorectal cancer. Its influence on patients with metastatic colorectal cancer (mCRC) is largely unexplored. Methods: 1231 patients participating in CALGB 80405 (first-line phase III chemotherapy trial for mCRC) completed questionnaires that included self-report on PA at time of chemotherapy initiation and total metabolic equivalent task (MET)-hours/week were determined based on responses. The primary endpoint of the clinical trial and this companion study was overall survival (OS), with progression-free survival (PFS) as a secondary endpoint. To minimize confounding by poor and rapidly declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and adjusted for known prognostic factors, comorbid illness, and weight loss over the previous six months. Results: Compared with patients engaged in less than three MET-hours/week of PA, patients engaged in 18 or more MET-hours/week experienced an adjusted hazard ratio for OS of 0.81 (95% CI 0.67 to 0.98, P for trend 0.03) and for PFS of 0.84 (95% CI 0.71 to 1.00, P for trend 0.03). Greater nonvigorous PA and walking duration were both associated with improved OS ( P for trend 0.01 and 0.04, respectively). Conclusions: In mCRC patients from CALGB 80405, greater total PA was associated with improved PFS and OS, while greater walking duration and non-vigorous PA were associated with reduced risk of all-cause mortality. Support: U10CA180821, U10CA180882. ClinicalTrials.gov ID: NCT00265850 [Table: see text]
Clinical significance of hyperpigmentation due to pemetrexed treatment in advanced nonsquamous non-small cell lung cancer in China.
Authors: Qiong Hu, Aiwu Li, Shengxiang Ren, Xiaoxia Chen, Guanghui Gao, David H. Garfield, Caicun Zhou
Journal: Journal of Clinical Oncology (2012)

e18123 Background: Previous publications have demonstrated the efficacy of pemetrexed (PEM) as first-line, second-line and maintenance therapy in advanced non-small cell lung cancer (NSCLC). A recent study found skin toxicities compromised continuation of PEM treatment. The purpose of this study is to investigate the clinical significance of hyperpigmentation (HP) in advanced nonsquamous (NS) NSCLC receiving PEM-based therapy in China. Methods: Medical records of patients with advanced NSNSCLC who received PEM-based treatment in Shanghai Pulmonary Hospital were retrospectively studied. Chi-square test, Pearson’s test as well as Kaplan-Meier method and Cox Proportional Hazards model were performed for statistical analysis. Results: A total of 101 patients were collected with a median age of 58 years old. Among them, 53 (52.5%) were female and 65 (64.4%) were nonsmokers. 52 (51.5%) patients received first-line treatment. Presence of HP was associated with better ORR (22% vs 7.1%, p=0.043) and DCR (84.7% vs 54.8%, p=0.001). Patients with HP had longer PFS (186 days versus 96 days, p&lt;0.0001). There were no significant differences according to grade of HP in ORR, DCR and PFS. There was a higher incidence of hyperpigmentation in patients who received first-line treatment (73.1%% vs 42.9%, p=0.023) and doublet agent (43.1% vs 74.0%, p=0.002). Multivariate analysis demonstrated HP was an independent factor for better clinical outcomes (vs absence, Hazard Ratio [HR] 0.417, 95% Confidential Interval [CI] 0.255-0.690, p=0.001). Conclusions: HP due to PEM is frequent in advanced NSNSCLC receiving PEM. It is an independent predictive factor for better clinical outcomes in Pemetrexed-treated advanced NSNSCLC in China.
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS‐R)
Authors: Xavier Calvo, Leonor Arenillas, Elisa Luño, Leonor Senent, Montserrat Arnan, Fernando Ramos, Carme Pedro, Mar Tormo, Julia Montoro, María Díez‐Campelo, María Laura Blanco, Beatriz Arrizabalaga, Blanca Xicoy, Santiago Bonanad, Andrés Jerez, Meritxell Nomdedeu, Ana Ferrer, Guillermo F Sanz, Lourdes Florensa
Journal: American Journal of Hematology (2017)

The Revised International Prognostic Scoring System (IPSS-R) has been recognized as the score with the best outcome prediction capability in MDS, but this brought new concerns about the accurate prognostication of patients classified into the intermediate risk category. The correct enumeration of blasts is essential in prognostication of MDS. Recent data evidenced that considering blasts from nonerythroid cellularity (NECs) improves outcome prediction in the context of IPSS and WHO classification. We assessed the percentage of blasts from total nucleated cells (TNCs) and NECs in 3924 MDS patients from the GESMD, 498 of whom were MDS with erythroid predominance (MDS-E). We assessed if calculating IPSS-R by enumerating blasts from NECs improves prognostication of MDS. Twenty-four percent of patients classified into the intermediate category were reclassified into higher-risk categories and showed shorter overall survival (OS) and time to AML evolution than those who remained into the intermediate one. Likewise, a better distribution of patients was observed, since lower-risk patients showed longer survivals than previously whereas higher-risk ones maintained the outcome expected in this poor prognostic group (median OS < 20 months). Furthermore, our approach was particularly useful for detecting patients at risk of dying with AML. Regarding MDS-E, 51% patients classified into the intermediate category were reclassified into higher-risk ones and showed shorter OS and time to AML. In this subgroup of MDS, IPSS-R was capable of splitting our series in five groups with significant differences in OS only when blasts were assessed from NECs. In conclusion, our easy-applicable approach improves prognostic assessment of MDS patients.
Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.
Authors: Yoshihiko Tomita, Sei Naito, Naoto Sassa, Atsushi Takahashi, Tsunenori Kondo, Takuya Koie, Wataru Obara, Yasuyuki Kobayashi, Jun Teishima, Masayuki Takahashi, Hideyasu Matsuyama, Takeshi Ueda, Kenya Yamaguchi, Takeshi Kishida, Ryoichi Shiroki, Takashi Saika, Nobuo Shinohara, Mototsugu Oya, Hiroomi Kanayama
Journal: Journal of Clinical Oncology (2017)

469 Background: SWITCH, a prospective, randomized sequential trial to evaluate SU/SO versus SO/SU, revealed no difference in first-line or total PFS or OS, but no direct comparison was obtained between 1st line sunitinib (SU) and sorafenib (SO) for clear cell (CC) metastatic renal cell carcinoma (mRCC). Methods: Treatment-naïve patients with CC mRCC, ECOG PS 0/1 and MSKCC favorable or intermediate risk were randomized to receive open-label SU/SO or SO/SU at the standard dosage and schedule. The primary endpoint was 1st line PFS, and secondary endpoints were total PFS and OS. The calculated sample size was 59 per group, with α = 0.05, β = 0.10, and a censoring rate of 15%. Results: Of 124 patients enrolled in this study from February 2010 to July 2012 from 39 institutions, 120 could be evaluated (SU/SO, 57 and SO/SU, 63). Baseline patients' characteristics in the SU/SO and SO/SU groups were as follows: favorable risk, 21% and 22%; and presence ofnephrectomy, 88% and 89%, respectively. First-line mPFS was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (HR, 0.67; 95% CI, 0.42–1.08; p= 0.095). There was no statistically significant difference in total (T)-PFS, 27.8 M, and 22.6 m (HR 0.73, CI 0.428-1.246; p=0.247), or OS 38.4 m and 30.9 m (HR 0.934, CI 0.588-1.485; p=0.773). Subgroup analyses showed that T-PFS was NR and 27.8 m (p=0.021) in the favorable risk, and 38.4 m and 16.1 m (p=0.009) in with less than 5 metastatic sites, 6.5 m and 13.6 m (p=0.025) without nephrectomy in the SU/SO and SO/SU groups, respectively. The most common adverse events (AEs) in case of first-line SU or SO (all grade, all cause) were hand–foot syndrome (71% vs. 86%), hypothyroidism (70% vs. 33%), fatigue (57% vs. 40%), hypertension (55% vs. 44%), and diarrhea (23% vs. 38%). AEs were generally lower during second-line therapy. Conclusions: There was no significant difference in first-line PFS, T-PFS, and OS between the two sequential treatments. Although fewer patients received second-line treatment in the SU/SO group, OS in this group was numerically longer than that in the SO/SU group. Clinical trial information: 01481870.
Neoadjuvant FOLFIRINOX and/or gemcitabine/nab-paclitaxel for advanced pancreatic adenocarcinoma.
Authors: Keli Turner, Sumana Narayanan, Kristopher Attwood, Steven N. Hochwald, Renuka V. Iyer, Moshim Kukar
Journal: Journal of Clinical Oncology (2017)

473 Background: Neoadjuvant chemotherapy is increasingly being utilized for locally advanced (LAPC)/borderline resectable pancreatic cancer (BRPC); however, long term follow up data is sparse. At our institution, we use FOLFIRINOX as the regimen of choice. Gemcitabine (Gem) and nab-Paclitaxel (Abraxane) is utilized in patients not suited for FOLFIRINOX or if they have poor radiographic response and/or develop significant toxicities to FOLFIRINOX. The aim of this study was to report our institutional experience with neoadjuvant therapy for patients with advanced pancreatic cancer. Methods: A retrospective review was performed of all patients with BRPC or LAPC who received FOLFIRINOX (or a modified regimen), Gem/nab-Paclitaxel, or both prior to surgical resection. FOLFIRINOX was typically given for 4 – 6 cycles while gem/nab-Paclitaxel was given for 2 cycles. Results: From January 2011 to December 2015, 39 patients were identified who met the study criteria. Eight patients received FOLFIRINOX alone (median age 62), 20 patients received FOLFIRINOX + Gem/nab-Paclitaxel, and 11 received only Gem/nab-Paclitaxel (median age 72). Eighteen patients (46%) completed the intended cycles of chemotherapy. Twenty two patients had a radiologic and/or biomarker response. Exploration was performed in 25 of 39 (64%) patients of whom 20 (51%) underwent curative resection. Of the 20 resected patients, there were no post-operative deaths. The median tumor size, median lymph node ratio, and R0 resection rates were 2.4 cm, 0, and 85% for the entire cohort. Median follow up was 20.7 months. The median overall survival for the resected cohort was not reached vs 13.5 months in the no resection group; two year overall survival for the resection vs. no resection groups was 87% vs 16% (p &lt; .001). Conclusions: FOLFIRINOX and/or Gemcitabine/nab-Paclitaxel as neoadjuvant therapy for LAPC/BRPC is fairly well tolerated, leads to appreciable rates of margin negative surgical resection, and a significant overall survival advantage.
Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).
Authors: Armando Santoro, Camillo Porta, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Richard S. Finn, Jean-Luc Raoul, Lawrence H. Schwartz, Aiwu Ruth He, Jorg Trojan, Markus Peck-Radosavljevic, Giovanni Abbadessa, Terri Robin Goldberg, Jordi Bruix
Journal: Journal of Clinical Oncology (2013)

TPS4159 Background: Tivantinibis a selective, non-ATP competitive, oral inhibitor of MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF). MET over-expression is associated with poor prognosis in HCC patients. A phase Ib study (Santoro et al, Br J Cancer, 2013) with tivantinib 360mg BID revealed no worsening of liver function in cirrhotic HCC pts. A randomized, placebo-controlled phase 2 study identified HCC patients with high tumor MET expression at immunohistochemistry (IHC) as the target population for tivantinib in second line (overall survival: 7.2 months on tivantinib, 3.8 months on placebo, HR: 0.38, p=0.01), and selected 240mg BID as the appropriate dose for HCC patients (Santoro et al, Lancet Oncol, 2013). Methods: Enrollment forthis phase III clinical trial (ARQ 197-A-U303, NCT01755767) has begun.Eligible pts must present with Child Pugh A; ECOG performance score &lt;1; inoperable RECIST 1.1 measurable disease; adequate bone marrow, liver and kidney functions; no prior liver transplant. Pts must have progressed after or not tolerated one prior line of systemic therapy including sorafenib and their tumor samples must be deemed MET-High by IHC at a central laboratory to be eligible. Approximately 303 pts are randomized 2:1 to receive tivantinib 240mg PO twice daily or placebo. Pts are stratified by vascular invasion, metastases, and alphafetoprotein level, and they are evaluated by CT or MRI scan at 8-week intervals. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival and safety. Treatment continues until confirmed disease progression or unacceptable toxicity. Pts discontinued from study treatment will be followed for survival. Participating centers are located in Europe, Australia, New Zealand, and the Americas. This trial is expected to complete enrollment by mid-2015, and an interim analysis is planned when approximately 60% of OS events are reached. Clinical trial information: NCT01755767.
Platelet Microparticles, Platelet Activation and Platelet-Leukocyte Conjugates in HIV Infected Patients with Optimal Response to Highly Active Antiretroviral Therapy (HAART).
Authors: Vicente F. Corrales-Medina, Jacques Simkins, Julio A. Chirinos, Bernardo Lopez-Sanabria, Stephen Symes, Dushyantha T. Jayaweera, Wenche Jy, Joaquin J. Jimenez, Lawrence L. Horstman, Yeon-Soong Ahn
Journal: Blood (2006)
Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia
Authors: Partow Kebriaei, Wei Wei, Peter F Thall, Celina Ledesma, Benigno C. Valdez, Uday R. Popat, Amanda L. Olson, Amin M. Alousi, Betul Oran, Sairah Ahmed, Stefan O. Ciurea, Krina Patel, Elizabeth J. Shpall, Chitra Hosing, Muzaffar H Qazilbash, Nina Shah, David Marin, Katayoun Rezvani, Yago Nieto, Richard E. Champlin, Borje S Andersson
Journal: Blood (2016)
ERCC-1 (E) expression and its effect on survival in patients (pts) receiving concurrent cisplatin (C) and radiation (R) for locally advanced head and neck cancer (HNC)
Authors: C. T. Lan, R. H. Amirkhan, T. Gray, Y. Xie, J. E. Dowell
Journal: Journal of Clinical Oncology (2009)

e17033 Background: E is a DNA repair gene involved in the nucleotide excision repair pathway. Overexpression of E has been associated with resistance to C in patients with ovarian, gastric, and lung cancer. We retrospectively analyzed tissue from HNC pts who received concurrent C and R to determine if E expression was a significant independent predictor of survival. Methods: Eligible HNC pts had squamous cell histology and received definitive concurrent C and R at the Dallas VAMC. Tissue was immunostained for E using ERCC-1,clone 8F, 1:100 dilution (Abcam, Cat#ab2356, Cambridge, MA) diluted in ChemMate buffer (Ventana Medical Systems, Tucson, AZ) on a BenchMarkXT automated immunostainer using the UltraVIEW system with horseradish peroxidase and diaminobenzidine (DAB) chromogen (Ventana Medical Systems, Tucson, AZ) per the standard protocol of the UT Southwestern Pathology Immunohistochemistry Laboratory. E scoring was determined by 2 pathologists blinded to clinical outcomes. Scoring was as follows: 0 = 0% of tumor nuclei were positive, 1+ = less than 50%, 2+ = 50–75% and 3+ = 75–100%. Results: 73 consecutively treated patients were analyzed. Median age 59 (range 41 - 80); 99% male; 7% stage II, 19% stage III, 73% stage IV; primary site - 4% oral cavity, 56% oropharynx, 14% hypopharynx, 23% larynx, 3% nasopharynx; Tumor grade - 60% moderately differentiated, 4% well differentiated, 15% poorly differentiated, 21% not specified; Performance status 0–25%, 1–45%, 2–8%, unknown-22%; E scoring was 0 in 0%, 1+ (14%), 2+ (42%), 3+ (44%). In univariate analysis, E staining 3+ was not predictive of survival with a hazard ratio (HR) of .796 (95% CI .44–1.43; p = 0.44). In multivariate analysis, the only significant predictor was hypopharynx with a HR of 3.18 (95% CI 1.02–9.88; p = 0.046). HR for age &gt; 60 was 2.16 (95% CI .96–4.86; p = 0.06). E staining 3+ was not predictive of survival with a HR of .69 (95% CI .3–1.56; p = 0.37). Median survival (MS) for the whole group was 2.8 years (y); 5y survival - 41%. MS for the E 3+ pts - 2.1y; 5y survival 38%. MS for the E &lt; 3+ pts - 2.9y; 5y survival 44% (p = not significant). Conclusions: In our retrospective review of HNC patients receiving concurrent C and R, E staining was not a significant predictor of survival. No significant financial relationships to disclose.
Expression of enhancer of zeste homologue 2, correlated with HIF-1α, to refine relapse risk and predict poor outcome for breast cancer.
Authors: Min Dong, XinJuan Fan, Zhan-Hong Chen, Xing Li, Tian tian Wang, Jie Chen, Qu Lin, Jing-Yun Wen, Xiao-Kun Ma, Li Wei, Dan-Yun Ruan, Ze-Xiao Lin, Quentin Liu, XiangBo Wan, Xiang-Yuan Wu
Journal: Journal of Clinical Oncology (2013)

538 Background: Overexpression of enhancer of zeste homologue 2 (EZH2), a key component of polycomb proteins, has been linked to aggressive tumor behavior for breast cancer. In vitro, hypoxia-inducible factor 1 alpha (HIF-1α) transcriptionally activates EZH2 and promotes breast tumor initiating cells progression. Here, we characterized the clinicopathological effect of HIF-1α and EZH2 in breast cancer patients. Methods: Tumor specimens from 410 luminal subtype breast cancer patients were used to construct tissue microarray. EZH2 and HIF-1α level were examined by immunohistochemistry staining and Western blot analysis. With the 5-year follow up, the prognostic effect of EZH2 was subjected to multivariate analysis. Results: EZH2 and HIF-1α were highly expressed in 99 (24.1%) and 272 (70.6%) patients, respectively. EZH2 overexpression was associated with high histological grade (P=0.030), lymphatic invasion (P=0.025), HER2 overexpression (P=0.005) and hypoxic condition (P&lt;0.001). Forced expression of EZH2 predicted a poor 5-year overall survival (OS, 74.8% vs. 93.4%, P=0.001), disease-free survival (DFS, 72.2% vs. 88.6%, P=0.031), local failure-free survival (LFFS, 95.7% vs. 97.9%, P=0.045) and distant metastasis-free survival (DMFS, 75.4% vs. 90.5%, P=0.039). However, the prognostic effect of HIF-1α was not detected for breast cancer. Cox multivariate analysis confirmed that EZH2 was an independent prognostic factor for OS, DFS and LFFS. Moreover, a positive correlation was detected between EZH2 and HIF-1α (r=0.299, P&lt;0.001). Importantly, tumors with HIF-1α and EZH2 co-overexpression were correlated with a worsened OS (P=0.007). Conclusions: EZH2 was an independent negative prognostic biomarker for luminal subtype breast cancer. Targeting HIF-1α transcriptionally regulated EZH2 pathway might be of benefit in the treatment of luminal subtype of breast cancer.